[go: up one dir, main page]

WO2019099454A3 - Highly functional antibody libraries - Google Patents

Highly functional antibody libraries Download PDF

Info

Publication number
WO2019099454A3
WO2019099454A3 PCT/US2018/060933 US2018060933W WO2019099454A3 WO 2019099454 A3 WO2019099454 A3 WO 2019099454A3 US 2018060933 W US2018060933 W US 2018060933W WO 2019099454 A3 WO2019099454 A3 WO 2019099454A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody libraries
highly functional
functional antibody
library
developability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/060933
Other languages
French (fr)
Other versions
WO2019099454A2 (en
Inventor
Philippe Valadon
Juan Carlos Almagro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2019099454A2 publication Critical patent/WO2019099454A2/en
Publication of WO2019099454A3 publication Critical patent/WO2019099454A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a method for the generation of antibody libraries of improved functionality and uses of thereof by combining a library of antibodies pre-selected for functional properties relevant to developability, such as for example improved thermal stability, with a library of CDR-H3 fragments.
PCT/US2018/060933 2017-11-15 2018-11-14 Highly functional antibody libraries Ceased WO2019099454A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586800P 2017-11-15 2017-11-15
US62/586,800 2017-11-15

Publications (2)

Publication Number Publication Date
WO2019099454A2 WO2019099454A2 (en) 2019-05-23
WO2019099454A3 true WO2019099454A3 (en) 2019-07-04

Family

ID=65409453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/060933 Ceased WO2019099454A2 (en) 2017-11-15 2018-11-14 Highly functional antibody libraries

Country Status (1)

Country Link
WO (1) WO2019099454A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056441A2 (en) * 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2009132287A2 (en) * 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
EP2728000A1 (en) * 2011-06-03 2014-05-07 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2564523T3 (en) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Design and generation of phage de novo human presentation libraries by fusion with pIX or pVII, vectors, antibodies and methods
JP2013508287A (en) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド Methods for affinity maturation of antibodies
RU2603080C2 (en) 2010-11-19 2016-11-20 МорфоСис АГ Collection and methods for its use
US8777044B1 (en) 2012-03-16 2014-07-15 Tommy Raymus Beverage container device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056441A2 (en) * 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2009132287A2 (en) * 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
EP2728000A1 (en) * 2011-06-03 2014-05-07 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAE YOUNG KIM ET AL: "Antibody light chain variable domains and their biophysically improved versions for human immunotherapy", MABS, vol. 6, no. 1, 20 January 2014 (2014-01-20), US, pages 219 - 235, XP055394573, ISSN: 1942-0870, DOI: 10.4161/mabs.26844 *
LAKHRIF ZINEB ET AL: "A method to confer Protein L binding ability to any antibody fragment.", MABS 2016, vol. 8, no. 2, 2016, pages 379 - 388, XP002791446, ISSN: 1942-0870 *
NELSON RENAE S ET AL: "A universal phage display system for the seamless construction of Fab libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 450, 26 July 2017 (2017-07-26), pages 41 - 49, XP085187524, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2017.07.011 *

Also Published As

Publication number Publication date
WO2019099454A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
EP4516809A3 (en) Bispecific antibodies specifically binding to pd1 and lag3
MX2019012953A (en) Bispecific antibody against ox40 and ctla-4.
EP4635984A3 (en) Altered virus
WO2019086500A3 (en) Bispecific 2+1 contorsbodies
MX2018013038A (en) Anti-il-33 antibodies, compositions, methods and uses thereof.
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
WO2015184001A8 (en) Anti-tnf-alpha glycoantibodies and uses thereof
EP4556020A3 (en) Antibody molecules
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
EP4400517A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
MX2018015272A (en) Anti-cd98 antibodies and antibody drug conjugates.
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX2018015268A (en) Anti-cd98 antibodies and antibody drug conjugates.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
NZ750244A (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
WO2012125733A3 (en) Antibody screening methods
NZ758093A (en) Monoclonal antibody to pd-l1
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2019008241A (en) A polypeptide linker for preparing multispecific antibodies.
JOP20200295A1 (en) Mono-specific and multispecific antibodies to the TMEFF2 antagonist and their uses
NZ710422A (en) Protein combination-based fv library, and preparation method therefor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18847161

Country of ref document: EP

Kind code of ref document: A2